RecruitingNCT07219927

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Sponsor

Supernus Pharmaceuticals, Inc.

Enrollment

120 participants

Start Date

Mar 31, 2025

Study Type

OBSERVATIONAL

Conditions

Parkinson Disease

Summary

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Participant has received a prescription for ONAPGO™ according to the standard of care.
Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form.
The HCP/Investigator determines the participant is an appropriate study participant.
Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day.

Exclusion Criteria4

Did not receive a prescription for ONAPGO™.
Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study.
Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron.
Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).